Amgenvs.Biogen
AMGN vs BIIB · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 7.3× larger than Biogen by market cap; Amgen trades at the lower P/E (25.8 vs 37.2); year to date, Amgen leads (+35.6% vs +23.9%).
Side by side
| AMGN | BIIB | |
|---|---|---|
| Market cap | $226B | $31B |
| Price | $442.24 | $220.77 |
| Today | −0.4% | +1.2% |
| Return YTD | +35.6% | +23.9% |
| Return 1Y | +51.1% | +56.6% |
| P/E | 25.8 | 37.2 |
| P/S | 5.9 | 3.1 |
| P/B | 19.3 | 1.6 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
AmgenAMGN
Long-established in biotech, with oncology and haematology at the centre of the portfolio, immunology beside it and a line in bone disease. MariTide is the obesity candidate in the pipeline.
Full AMGN profile →BiogenBIIB
Neurological disease is the whole focus, from multiple sclerosis to Alzheimer's, where Leqembi is partnered with Eisai.
Full BIIB profile →More AMGN & BIIB comparisons
Other head-to-heads in the Biotech & innovation segment.
See where AMGN and BIIB sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →